https://nouscom.com/2018/05/09/immune-profiling-of-premalignant-lesions-in-patients-with-lynch-syndrome/ 2018-05-15T14:04:04+00:00 https://nouscom.com/2017/05/17/nouscom-concludes-successful-series-a-financing-of-eur-12-million/ 2018-05-21T10:57:45+00:00 https://nouscom.com/2017/11/13/nouscoms-neoantigen-based-vaccine-synergizes-with-nktr-214-to-cure-established-tumors-in-preclinical-model/ 2018-05-21T11:02:53+00:00 https://nouscom.com/2016/04/28/a-monovalent-chimpanzee-adenovirus-ebola-vaccine-boosted-with-mva/ 2018-05-24T14:00:39+00:00 https://nouscom.com/2016/03/10/efficacy-of-a-virus-vectored-vaccine-against-human-and-bovine-respiratory-syncytial-virus-infections/ 2018-05-24T14:00:46+00:00 https://nouscom.com/2016/02/12/chimpanzee-adenovirus-and-mva-vectored-respiratory-syncytial-virus-vaccine-is-safe-and-expands-humoral-and-cellular-immunity-in-adults/ 2018-05-24T14:00:51+00:00 https://nouscom.com/2014/11/05/a-human-vaccine-strategy-based-on-chimpanzee-adenoviral-and-mva-vectors-that-primes-boosts-and-sustains-functional-hcv-specific-t-cell-memory/ 2018-05-24T14:00:59+00:00 https://nouscom.com/2014/09/07/chimpanzee-adenovirus-vaccine-generates-acute-and-durable-protective-immunity-against-ebolavirus-challenge/ 2018-05-24T14:01:11+00:00 https://nouscom.com/2013/11/28/protective-cd8th-t-cell-immunity-to-human-malaria-induced-by-chimpanzee-adenovirus-mva-immunisation-2/ 2018-05-24T14:01:17+00:00 https://nouscom.com/2012/01/04/vaccine-vectors-derived-from-a-large-collection-of-simian-adenoviruses-induce-potent-cellular-immunity-across-multiple-species/ 2018-05-24T14:01:22+00:00 https://nouscom.com/2017/09/26/nouscom-appoints-new-chief-operating-officer-and-strengthens-the-board-of-directors/ 2018-05-31T15:53:56+00:00 https://nouscom.com/2017/11/06/nouscom-raises-e42-million-series-b-financing/ 2018-05-31T16:00:08+00:00 https://nouscom.com/2018/10/23/nouscom-will-present-at-the-world-vaccine-congress-europe-2018/ 2018-10-23T13:47:59+00:00 https://nouscom.com/2018/11/05/nouscom-strengthens-board-of-directors-with-the-appointment-of-john-f-mcdonald-as-an-independent-director/ 2018-11-05T07:05:58+00:00 https://nouscom.com/2018/11/08/nouscom-will-present-at-the-neoag-summit-2018/ 2019-04-11T11:19:33+00:00 https://nouscom.com/wp-content/uploads/2018/11/asdasd.jpg https://nouscom.com/2019/11/01/nouscom-will-join-present-at-the-sitc-2019/ 2019-11-01T12:35:36+00:00 https://nouscom.com/2019/12/09/nouscom-first-patient-dosed-in-a-phase-1-trial-with-nous-209-an-off-the-shelf-neoantigen-cancer-vaccine-in-msi-high-solid-tumors/ 2019-12-09T07:00:51+00:00 https://nouscom.com/2019/06/03/nouscom-ind-for-nous-209-an-off-the-shelf-neoantigen-cancer-vaccine-cleared-by-fda-to-commence-clinical-development-in-msi-solid-tumors/ 2020-02-25T15:44:06+00:00 https://nouscom.com/2020/12/01/new-viral-vectors-for-infectious-diseases-and-cancer/ 2020-12-08T11:44:46+00:00 https://nouscom.com/2020/12/08/retargeted-and-multi-cytokine-armed-herpes-virus-is-a-potent-cancer-endovaccine-for-local-and-systemic-anti-tumor-treatment/ 2020-12-08T12:08:12+00:00 https://nouscom.com/2020/12/11/nouscom-appoints-goran-ando-md-as-chairman-and-richard-davis-phd-as-chief-business-officer/ 2020-12-11T07:00:41+00:00 https://nouscom.com/2021/03/11/nouscom-receives-approval-to-begin-phase-1b-trials-of-nous-pev-a-novel-personalized-cancer-immunotherapy/ 2021-03-11T08:48:48+00:00 https://nouscom.com/2021/06/22/dr-anna-morena-dalise-will-join-as-expert-speaker-at-the-next-generation-cancer-vaccine-development-summit/ 2021-06-22T07:15:59+00:00 https://nouscom.com/2021/08/10/nouscom-highlights-innovative-science-behind-venus-its-novel-algorithm-for-identifying-and-prioritizing-patient-specific-tumor-neoantigens-for-personalized-cancer-immunotherapy/ 2021-08-17T10:23:34+00:00 https://nouscom.com/2021/08/24/nouscom-announces-first-patient-dosed-in-a-phase-1b-trial-with-nous-pev-a-novel-personalized-cancer-immunotherapy-in-advanced-melanoma-or-lung-cancer/ 2021-08-24T08:01:01+00:00 https://nouscom.com/2021/11/26/maximizing-cancer-therapy-via-complementary-mechanisms-of-immune-activation-pd-1-blockade-neoantigen-vaccination-and-tregs-depletion/ 2021-11-26T11:37:26+00:00 https://nouscom.com/2022/05/23/nouscom-announces-promotion-of-richard-davis-to-chief-operating-officer/ 2022-05-23T07:00:02+00:00 https://nouscom.com/2022/05/27/nouscom-to-present-full-phase-1-data-of-nous-209-an-off-the-shelf-neoantigen-cancer-immunotherapy-for-the-treatment-of-dmmr-msi-h-solid-tumors-at-asco-2022/ 2022-05-27T08:32:32+00:00 https://nouscom.com/2022/09/05/nouscom-new-science-translational-medicine-publication-highlighted-on-cancer-discovery-researchwatch/ 2022-09-05T09:10:18+00:00 https://nouscom.com/2022/09/09/nouscom-strengthens-leadership-team-with-the-appointments-of-sven-gogov-md-as-chief-medical-officer-and-maria-arce-tomas-phd-as-vp-head-of-regulatory-affairs/ 2022-09-09T07:00:07+00:00 https://nouscom.com/2022/09/27/immune-profiling-of-premalignant-lesions-in-patients-with-lynch-syndrome-2/ 2022-09-27T10:09:33+00:00 https://nouscom.com/2022/09/27/adenoviral-vaccine-targeting-multiple-neoantigens-as-strategy-to-eradicate-large-tumors-combined-with-checkpoint-blockade/ 2022-09-27T13:32:52+00:00 https://nouscom.com/2022/09/27/new-viral-vectors-for-infectious-diseases-and-cancer-2-2/ 2022-09-27T13:32:57+00:00 https://nouscom.com/2022/09/27/a-genetic-vaccine-encoding-shared-cancer-neoantigens-to-treat-tumors-with-microsatellite-instability/ 2022-09-27T13:33:47+00:00 https://nouscom.com/2022/09/27/venus-a-novel-selection-approach-to-improve-the-accuracy-of-neoantigens-prediction-2/ 2022-09-27T13:33:56+00:00 https://nouscom.com/2022/09/27/adenoviral-based-vaccine-promotes-neoantigen-specific-cd8-t-cell-stemness-and-tumor-rejection-2/ 2022-09-27T13:34:01+00:00 https://nouscom.com/2022/09/27/nouscom-poster-presentation-at-cimt-2022/ 2022-09-27T13:35:15+00:00 https://nouscom.com/2022/11/15/nouscom-announces-first-patient-dosed-in-phase-2-randomized-trial-with-nous-209-an-off-the-shelf-neoantigen-cancer-immunotherapy-in-dmmr-msi-high-metastatic-colorectal-cancer/ 2022-11-15T08:00:55+00:00 https://nouscom.com/2023/01/05/nouscom-announces-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-nous-209-in-combination-with-keytruda-pembrolizumab-in-a-phase-2-randomized-trials-in-dmmr-msi-high-met/ 2023-01-05T12:34:16+00:00 https://nouscom.com/2023/10/25/getting-personal-in-metastatic-melanoma-neoantigen-based-vaccines-as-a-new-therapeutic-strategy/ 2023-10-25T10:27:22+00:00 https://nouscom.com/2023/10/25/adenovirus-encoded-adjuvant-adena-anti-ctla-4-a-novel-strategy-to-improve-adenovirus-based-vaccines-against-infectious-diseases-and-cancer/ 2023-10-25T10:30:48+00:00 https://nouscom.com/2023/10/25/vector-aided-microenvironment-programming-vamp-reprogramming-the-tme-with-mva-virus-expressing-il-12-for-effective-antitumor-activity/ 2023-10-25T10:30:53+00:00 https://nouscom.com/2023/10/25/dr-elisa-scarselli-nouscom-cso-invited-speaker-at-ehtg-european-hereditary-tumour-group-2023-vilnius-september-28-october-1st/ 2023-10-27T15:51:54+00:00 https://nouscom.com/2023/10/25/nouscom-poster-presentation-at-cicon23-international-cancer-immunotherapy-conference-milan-september-20-23/ 2023-10-27T15:55:12+00:00 https://nouscom.com/2022/12/07/dr-marina-udier-comments-the-neoantigen-vaccine-report-card-issued-by-biocentury/ 2023-11-10T10:37:13+00:00 https://nouscom.com/2016/05/12/nouscom-presents-at-the-1st-meeting-of-the-european-hereditary-tumour-group-ehtg-2/ 2023-11-10T10:43:46+00:00 https://nouscom.com/2017/09/26/nouscom-presents-at-agenda-sachs-forum-2/ 2023-11-10T10:46:09+00:00 https://nouscom.com/2017/02/25/nouscom-presents-at-agenda-sachs-forum/ 2023-11-10T10:46:14+00:00 https://nouscom.com/2023/10/25/dr-rosa-vitale-invited-speaker-at-vaccines-europe-2023-berlin-september-13-15/ 2023-11-10T10:47:12+00:00 https://nouscom.com/2023/10/25/dr-elisa-scarselli-cso-of-nouscom-invited-speaker-immunotherapy-in-hematological-malignancies-2023-ccitc-cuneo-may-18-20/ 2023-11-10T10:47:14+00:00 https://nouscom.com/2023/10/25/dr-guido-leoni-bioinformatic-lead-presenting-at-the-mrna-cancer-vaccines-summit-2023-boston-oct-10-12/ 2023-11-10T10:47:19+00:00 https://nouscom.com/2021/03/09/nouscom-is-presenting-at-the-virtual-spring-private-company-showcase-2021-on-march-11th/ 2023-11-10T10:47:25+00:00 https://nouscom.com/2021/03/09/nouscom-is-presenting-at-the-biocapital-europe-2021-on-march-11th/ 2023-11-10T10:47:30+00:00 https://nouscom.com/2019/10/08/nouscom-will-present-at-the-2nd-european-oncology-and-immono-oncology-drug-discovery-symposium/ 2023-11-10T10:47:35+00:00 https://nouscom.com/2019/10/07/nouscom-is-presenting-at-the-tmb-neoantigen-congress/ 2023-11-10T10:47:40+00:00 https://nouscom.com/2018/11/08/nouscom-will-present-at-the-neoag-summit-2018-2/ 2023-11-10T10:47:46+00:00 https://nouscom.com/2018/02/06/nouscom-will-present-at-biocapital-europe/ 2023-11-10T10:47:54+00:00 https://nouscom.com/2017/09/06/nouscom-presents-at-3rd-cri-cimt-eati-aacr-international-cancer-immunotherapy-conference/ 2023-11-10T10:48:00+00:00 https://nouscom.com/2017/06/02/nouscom-presents-at-3rd-annual-immuno-oncology-bdl-and-investment-forum/ 2023-11-10T10:48:05+00:00 https://nouscom.com/2017/02/02/nouscom-presents-at-embl-cancer-core-europe-conference-cancer-immunotherapy-2/ 2023-11-10T10:48:10+00:00 https://nouscom.com/2023/03/15/nouscom-announces-aacr-2023-late-breaking-presentation-of-translational-phase-1b-data-of-nous-pev-a-personalized-neoantigen-cancer-immunotherapy/ 2023-11-10T10:54:49+00:00 https://nouscom.com/2023/11/10/nouscom-presentation-of-a-late-breaking-abstract-on-translational-phase-1b-data-of-nous-pev-a-personalized-neoantigen-cancer-immunotherapy-at-aacr-2023-2/ 2023-11-10T11:16:17+00:00 https://nouscom.com/2022/09/27/nouscom-poster-presentation-of-full-phase-1-data-of-nous-209-an-off-the-shelf-neoantigen-cancer-immunotherapy-for-the-treatment-of-dmmr-msi-h-solid-tumors-at-asco-2022-2/ 2023-11-12T10:44:15+00:00 https://nouscom.com/2021/10/15/dr-elisa-scarselli-will-join-as-expert-speaker-at-the-virtual-neoantigen-based-therapies-summit/ 2023-11-12T11:05:30+00:00 https://nouscom.com/2021/09/27/nouscom-poster-presentation-at-sitc-2021/ 2023-11-12T11:05:35+00:00 https://nouscom.com/2021/09/27/nouscom-poster-presentation-at-esmo-2021/ 2023-11-12T11:12:16+00:00 https://nouscom.com/2023/10/25/dr-elisa-scarselli-cso-invited-speaker-at-vaccines-europe-2023-berlin-september-13-15/ 2023-11-12T11:20:00+00:00 https://nouscom.com/2023/10/25/dr-morena-dalise-vp-of-immunology-presented-as-invited-expert-speaker-at-the-annual-neoantigen-summit-europe-amsterdam-april-24-26/ 2023-11-12T11:20:42+00:00 https://nouscom.com/2023/11/10/nouscom-poster-presentation-on-nous-pev-personalized-neoantigen-cancer-vaccine-selected-for-poster-presentation-at-sitc-2022/ 2023-11-12T11:22:49+00:00 https://nouscom.com/2023/10/25/dr-gabriella-cotugno-vector-construction-lead-presenting-at-esgct-european-society-of-gene-and-cell-therapy-annual-congress-2023-brussels-oct-24-27-2/ 2023-11-12T11:24:32+00:00 https://nouscom.com/2023/10/25/nouscom-poster-presentation-at-esgct-european-society-of-gene-and-cell-therapy-annual-congress-2023-brussels-oct-24-27/ 2023-11-12T11:25:15+00:00 https://nouscom.com/2023/10/25/nouscom-poster-presentation-at-15th-international-adenovirus-meeting-brac-september-22-28/ 2023-11-12T11:25:23+00:00 https://nouscom.com/2023/10/25/nouscom-poster-presentation-at-eacr-annual-congress-of-the-european-association-for-cancer-research-2023-turin-june-11-14/ 2023-11-12T11:25:29+00:00 https://nouscom.com/2021/05/18/nouscom-is-presenting-at-the-virtual-spring-private-company-showcase-2021-on-march-11th-2/ 2023-11-12T11:32:29+00:00 https://nouscom.com/2019/05/21/dr-marina-udier-coo-of-nouscom-will-give-a-talk-about-our-company-at-the-baselarea-swiss-life-science-event-on-june-20-2019-in-basel/ 2023-11-12T11:32:49+00:00 https://nouscom.com/2021/10/01/dr-marina-udier-looks-forward-to-presenting-chardan-for-their-5th-annual-genetic-medicines-conference-on-october-4th-at-3-pm-cet/ 2023-11-12T11:33:23+00:00 https://nouscom.com/2022/09/27/nouscom-poster-presentation-of-translational-phase-1-data-of-nous-209-an-off-the-shelf-neoantigen-cancer-vaccine-for-the-treatment-of-msi-h-solid-tumors-at-aacr-2022/ 2023-11-13T13:09:07+00:00 https://nouscom.com/2023/11/22/personalized-cancer-vaccines-go-viral-viral-vectors-in-the-era-of-personalized-immunotherapy-of-cancer/ 2023-11-22T15:00:26+00:00 https://nouscom.com/2024/02/26/tumor-burden-dictates-the-neoantigen-features-required-to-generate-an-effective-cancer-vaccine-2/ 2024-02-26T10:11:59+00:00 https://nouscom.com/2023/11/10/dr-gabriella-cotugno-vector-construction-lead-presenting-at-esgct-european-society-of-gene-and-cell-therapy-annual-congress-2023-brussels-oct-24-27-3/ 2024-06-28T06:52:16+00:00 https://nouscom.com/2023/11/10/phase-i-trial-of-viral-vector-based-personalized-vaccination-elicits-robust-neoantigen-specific-antitumor-t-cell-responses/ 2024-06-28T06:56:29+00:00 https://nouscom.com/2024/07/17/nouscom-appoints-tiffany-muller-as-chief-financial-officer-and-loredana-siani-as-senior-vice-president-technical-and-cmc-development-2/ 2024-07-17T07:00:49+00:00 https://nouscom.com/2024/05/08/nouscom-appoints-leading-cancer-drug-development-expert-neil-gallagher-md-phd-as-independent-advisor-to-its-board-and-chair-of-its-rd-committee-2/ 2024-08-23T15:04:23+00:00 https://nouscom.com/2023/11/14/nouscom-raises-e67-5-million-72-million-in-oversubscribed-series-c-financing-round-2-2/ 2024-08-23T15:05:11+00:00 https://nouscom.com/2023/10/31/nouscoms-off-the-shelf-cancer-vaccine-nous-209-shows-potential-to-intercept-cancer-in-subjects-with-lynch-syndrome/ 2024-08-23T15:05:58+00:00 https://nouscom.com/2023/03/08/nouscom-announces-the-promotions-of-loredana-siani-to-vice-president-of-technical-and-cmc-development-tiffany-brooke-muller-to-senior-vice-president-of-finance-and-morena-dalise-to-vice-pres/ 2024-08-23T15:07:14+00:00 https://nouscom.com/2023/03/01/nouscom-announces-appointment-of-sarah-runswick-as-senior-director-of-clinical-science/ 2024-08-23T15:07:56+00:00 https://nouscom.com/2023/01/19/nouscom-announces-appointment-of-yen-ching-as-vice-president-of-clinical-operations/ 2024-08-23T15:09:40+00:00 https://nouscom.com/2022/11/07/nouscoms-personalized-neoantigen-cancer-immunotherapy-nous-pev-demonstrates-promising-safety-immunogenicity-and-anti-tumor-activity-in-solid-tumors/ 2024-08-23T15:10:34+00:00 https://nouscom.com/2022/08/11/nouscom-announces-leading-publication-revealing-an-immune-mechanism-of-action-driving-anti-tumor-activity-of-adenovirus-vectored-vaccines-and-anti-pd1-immunotherapy/ 2024-08-23T15:11:12+00:00 https://nouscom.com/2022/06/06/nouscom-announces-positive-phase-1-data-of-nous-209-an-off-the-shelf-neoantigen-cancer-immunotherapy-for-the-treatment-of-dmmr-msi-h-solid-tumors-at-asco-2022/ 2024-08-23T15:11:46+00:00 https://nouscom.com/2022/05/17/nouscom-announces-janssen-receives-us-fda-ind-clearance-for-vac85135-an-off-the-shelf-cancer-immunotherapy-developed-using-nouscoms-proprietary-viral-vector-platform/ 2024-08-23T15:12:33+00:00 https://nouscom.com/2021/11/10/nouscom-to-present-interim-data-from-phase-1-trial-evaluating-nous-209-an-off-the-shelf-neoantigen-cancer-vaccine-for-the-treatment-of-msi-h-solid-tumors/ 2024-08-23T15:12:57+00:00 https://nouscom.com/2021/09/06/nouscom-ag-abstract-on-initial-results-from-phase-1-trial-for-nous-209-an-off-the-shelf-neoantigen-cancer-vaccine-in-msi-h-solid-tumors-will-be-presented-at-esmo/ 2024-08-23T15:15:42+00:00 https://nouscom.com/2020/07/22/nouscom-highlights-cutting-edge-science-that-led-to-the-design-of-nous-209-a-potential-off-the-shelf-neoantigen-cancer-vaccine-for-tumors-with-microsatellite-instability/ 2024-08-23T15:18:20+00:00 https://nouscom.com/2020/02/26/nouscom-strengthens-its-management-team/ 2024-08-23T15:19:24+00:00 https://nouscom.com/2019/06/19/nouscom-demonstrates-preclinical-proof-of-concept-for-personalized-cancer-neoantigen-vaccine-in-combination-with-immune-checkpoint-blockade-to-eradicate-large-tumors/ 2024-08-23T15:20:02+00:00 https://nouscom.com/2018/06/26/probiogen-nouscom-license-agreement/ 2024-08-23T15:20:50+00:00 https://nouscom.com/2018/05/04/okairos-awarded-by-swiss-biotech-association/ 2024-08-23T15:21:25+00:00 https://nouscom.com/2024/10/04/nouscom-to-present-updated-positive-data-on-nous-209s-potential-to-intercept-cancer-in-lynch-syndrome-carriers-at-sitc-2024-2/ 2024-10-04T08:59:47+00:00 https://nouscom.com/2024/11/05/nouscoms-off-the-shelf-neoantigen-immunotherapy-nous-209-continues-to-elicit-potent-and-durable-immune-responses-in-lynch-syndrome-carriers-highlighting-its-potential-to-intercept/ 2024-11-05T14:00:47+00:00 https://nouscom.com/2024/11/19/nouscom-completes-patient-enrollment-of-randomized-phase-2-study-evaluating-nous-209-an-off-the-shelf-neoantigen-immunotherapy-in-dmmr-msi-metastatic-colorectal-cancer-2/ 2024-11-19T08:00:47+00:00 https://nouscom.com/2024/12/03/nouscom-appoints-seasoned-executive-eckhard-niemeier-as-chief-business-officer/ 2024-12-03T08:01:20+00:00 https://nouscom.com/2025/03/25/nouscom-to-present-final-results-from-successful-phase-ib-ii-trial-of-nous-209-in-people-living-with-lynch-syndrome-demonstrating-powerful-potential-to-intercept-cancer-in-its-earliest-stages-of-dev-2/ 2025-03-25T20:29:41+00:00 https://nouscom.com/2025/04/29/nouscom-presents-positive-final-results-from-completed-phase-ib-ii-study-of-neoantigen-immunotherapy-nous-209-at-aacr-2025-demonstrating-a-highly-potent-and-durable-immune-response-in-lynch-syndrome-2/ 2025-04-29T07:29:41+00:00 https://nouscom.com/2025/10/13/nouscom-presents-positive-phase-2-results-of-nous-209-immunotherapy-combined-with-pembrolizumab-in-msi-h-metastatic-colorectal-cancer-patients-refractory-to-anti-pd-1-therapy-at-esmo-2025-2/ 2025-10-12T22:04:41+00:00 https://nouscom.com/2025/10/30/nouscom-to-present-new-positive-phase-1b-2-clinical-and-translational-data-on-nous-209-immunogenicity-and-cancer-interception-potential-in-lynch-syndrome-carriers-at-sitc-2025-2/ 2025-10-30T13:00:41+00:00 https://nouscom.com/2025/11/07/nouscom-presents-new-positive-phase-1-2b-data-of-nous-209-at-sitc-2025-supporting-plans-to-initiate-registration-enabling-study-for-cancer-interception-in-lynch-syndrome-carriers-2/ 2025-11-07T14:00:41+00:00 https://nouscom.com/2026/01/16/nouscom-highlights-potential-of-nous-209-to-intercept-cancer-in-lynch-syndrome-carriers-in-seminal-nature-medicine-publication-2/ 2026-01-16T09:59:41+00:00 https://nouscom.com/2025/11/29/neoadjuvant-personalized-viral-vaccine-prevents-tumor-relapse-in-checkpoint-resistant-murine-melanoma-model/ 2026-02-02T14:57:56+00:00 https://nouscom.com/2026/01/16/nous-209-neoantigen-vaccine-for-cancer-prevention-in-lynch-syndrome-carriers-a-phase-1b-2-trial/ 2026-02-02T14:58:47+00:00 https://nouscom.com/2025/09/28/nous-209-off-the-shelf-immunotherapy-has-the-potential-to-hit-primary-and-metachronous-colorectal-and-urothelial-cancers-in-lynch-syndrome/ 2026-02-03T09:28:46+00:00 https://nouscom.com/2026/06/01/nouscom-receives-u-s-fda-fast-track-designation-for-nous-209-a-novel-immunotherapy-for-the-prevention-of-lynch-syndrome-associated-cancers-2/ 2026-06-01T11:00:41+00:00 https://nouscom.com/2026/07/20/nouscom-selected-for-oral-presentation-on-nous-209-re-treatment-and-long-term-follow-up-in-lynch-syndrome-carriers-at-esmo-congress-2026/ 2026-07-20T11:00:41+00:00